Semi-Automatic Biopsy Instrument Market Size, Share, Growth, and Industry Analysis, By Types (Diameter 14G, Diameter 16G, Diameter 18G, Diameter 20G), By Applications (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers), and Regional Insights and Forecast to 2034
- Last Updated: 27-October-2026
- Base Year: 2025
- Historical Data: 2021-2024
- Region: Global
- Format: PDF
- Report ID: GGI113079
- SKU ID: 25504826
- Pages: 94
Download FREE Sample
Semi-Automatic Biopsy Instrument Market Size
The Global Semi-Automatic Biopsy Instrument Market size was USD 117.52 Million in 2025 and is projected to reach USD 121.63 Million in 2026, followed by USD 125.89 Million in 2027, before advancing to USD 165.77 Million by 2035, exhibiting a CAGR of 3.5% during the forecast period from 2026 to 2035.
The Semi-Automatic Biopsy Instrument Market is progressing as healthcare providers place greater emphasis on reliable tissue acquisition, controlled needle deployment, procedural efficiency, and minimally invasive diagnostic workflows. Core needle biopsy procedures continue to support instrument utilization across breast, liver, prostate, kidney, lung, lymph-node, and other soft-tissue assessments. Approximately 64% of demand is associated with routine hospital and diagnostic-center biopsy workflows, while nearly 36% is linked with specialized, research-oriented, or comparatively lower-volume procedures. Semi-automatic instruments remain relevant where physicians value manual positioning combined with controlled sampling activation.
![]()
In the US Semi-Automatic Biopsy Instrument Market, demand is supported by high diagnostic imaging penetration, established cancer screening pathways, and extensive outpatient biopsy infrastructure. Hospitals and dedicated diagnostic facilities collectively account for an estimated 82% of domestic instrument utilization, while image-guided procedures represent approximately 68% of biopsy workflows suitable for semi-automatic devices. Preference for controlled firing mechanisms and ergonomic disposable instruments continues to sustain replacement demand.
Semi-automatic biopsy instruments occupy a distinct position between fully manual needles and automatic biopsy guns because clinicians retain greater control over needle placement before specimen capture. Approximately 61% of purchasing decisions emphasize deployment consistency and specimen quality, while around 39% place stronger weight on handling, compatibility, procurement cost, and procedural convenience. This balance supports continued product differentiation around needle geometry, penetration control, echogenic visibility, safety mechanisms, and single-use configurations.
Key Findings
- Starting at USD 121.63 Million in 2026, the global Semi-Automatic Biopsy Instrument Market is expected to progress steadily, reaching USD 125.89 Million in 2027 and projected to reach USD 165.77 Million by 2035. The market is expected to expand at a CAGR of 3.5% throughout the forecast period from 2026 to 2035.
- Demand for semi-automatic biopsy instruments is increasing as healthcare providers expand minimally invasive tissue-sampling procedures across oncology, radiology, and pathology workflows. Hospitals account for approximately 58% of overall market demand, while diagnostic and imaging centers represent nearly 28%, supported by increasing utilization of image-guided biopsy procedures.
- Semi-automatic biopsy instruments provide physicians with controlled needle positioning before tissue capture, supporting procedural accuracy and specimen acquisition. Diameter 18G instruments represent approximately 39% of market demand, while Diameter 16G products account for nearly 26%, reflecting their broad suitability across soft-tissue and image-guided biopsy procedures.
- Growth in cancer diagnostics, outpatient biopsy services, imaging infrastructure, and disposable medical devices is supporting market expansion. Approximately 67% of relevant biopsy procedures involve image-guided workflows, while single-use configurations represent nearly 72% of applicable product preference as healthcare facilities prioritize infection control, procedural efficiency, and simplified preparation.
- North America accounts for approximately 38% of the global Semi-Automatic Biopsy Instrument Market, supported by mature oncology diagnostics and extensive imaging infrastructure. Europe represents approximately 27%, Asia-Pacific holds nearly 25%, and Middle East & Africa accounts for around 10% of global market demand.
Clinical usability remains a major competitive factor in the Semi-Automatic Biopsy Instrument Market. Around 59% of product-selection considerations are associated with sample reliability, needle visibility, penetration control, and physician handling, demonstrating that purchasing decisions extend beyond basic needle dimensions. Single-use configurations continue to gain importance as infection-control practices and simplified procedure preparation influence purchasing. Approximately 72% of applicable procedures favor disposable biopsy components, while reusable supporting equipment retains relevance where institutions prioritize controlled operating costs and established sterilization infrastructure.
![]()
Semi-Automatic Biopsy Instrument Market Trends
The Semi-Automatic Biopsy Instrument Market is increasingly shaped by precision-oriented diagnostic pathways rather than simple procedural volume. Clinicians require devices that combine predictable needle advancement with sufficient manual control to position the instrument accurately before tissue capture. Approximately 67% of suitable biopsy procedures are performed with imaging assistance, increasing the importance of echogenic needle characteristics, predictable deployment, and compatibility with ultrasound-guided workflows. Disposable configurations represent roughly 72% of relevant product usage as hospitals and diagnostic centers prioritize infection-control efficiency and reduced instrument reprocessing. Product design is consequently moving toward smoother penetration, secure depth adjustment, ergonomic grips, lightweight construction, and mechanisms that reduce accidental firing. Another important trend is the movement of appropriate tissue-sampling procedures toward outpatient environments. Around 31% of incremental procedural demand is associated with ambulatory or specialized diagnostic settings, encouraging suppliers to offer instruments that require limited preparation and can be incorporated into standardized procedure kits.
Needle selection is also becoming more procedure-specific. Diameter 18G products account for approximately 39% of demand because they offer a practical balance between tissue volume and procedural manageability across several common biopsy applications. Meanwhile, clinicians performing procedures requiring larger tissue cores continue to use 14G and 16G instruments, while 20G devices address applications where reduced needle diameter is preferred. Procurement departments increasingly evaluate total procedural efficiency alongside unit performance, and approximately 44% of competitive differentiation is associated with ergonomic design, deployment consistency, specimen adequacy, and imaging visibility. Manufacturers are therefore focusing on refinements rather than radical changes to the underlying mechanism. Greater standardization of biopsy protocols is simultaneously encouraging hospitals to rationalize product portfolios, creating advantages for suppliers capable of supporting several gauge sizes within consistent operating platforms.
Semi-Automatic Biopsy Instrument Market Dynamics
Expansion of image-guided and outpatient biopsy services
Expansion of ultrasound-guided procedures, ambulatory diagnostic services, and cancer-screening infrastructure creates a significant opportunity for semi-automatic biopsy instruments. Approximately 67% of relevant tissue-sampling procedures increasingly involve image guidance, while nearly 31% of emerging procedural capacity is associated with outpatient or specialized diagnostic environments. Semi-automatic designs are well positioned in these settings because clinicians can position the needle before controlled sample deployment. Growth opportunities are particularly visible in healthcare systems expanding radiology capacity, breast diagnostic programs, and minimally invasive oncology pathways. Manufacturers offering multiple gauge options, enhanced echogenicity, compact packaging, and straightforward activation mechanisms can address both established institutions and developing diagnostic networks.
Increasing requirement for minimally invasive tissue diagnosis
Growing dependence on histopathological confirmation in oncology and other disease areas is strengthening procedural demand for dependable core biopsy instruments. Approximately 64% of semi-automatic instrument consumption is connected with routine hospital and diagnostic-center tissue acquisition, demonstrating the importance of established biopsy pathways. At the same time, around 58% of application demand originates from hospitals where radiologists, surgeons, oncologists, and pathologists participate in coordinated diagnostic workflows. Semi-automatic devices benefit from the continuing preference for minimally invasive sampling because they combine controlled positioning with rapid specimen capture. Broader imaging availability and increased emphasis on earlier diagnostic intervention further support instrument utilization across both mature and developing healthcare systems.
| Market Driver | Impact Rank | Contribution | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Rising demand for minimally invasive tissue diagnosis and core biopsy procedures | High | 1.62% | High | High | High |
| Expansion of cancer screening, early detection and histopathology programs | High | 1.34% | High | High | High |
| Increasing adoption of ultrasound and other image-guided biopsy procedures | Medium | 1.12% | Medium | High | High |
| Expansion of outpatient diagnostic and specialized imaging centers | Medium | 0.91% | Medium | Medium | High |
| Improvements in needle ergonomics, echogenic visibility and specimen acquisition | Low | 0.66% | Low | Medium | Medium |
| Others | Lowest | 0.35% | Low | Low | Medium |
| Total Driver Contribution | 6.00% |
Market Restraints
"Competition from fully automatic biopsy systems and procedural alternatives"
Competitive pressure from automatic biopsy guns, vacuum-assisted systems, fine-needle aspiration products, and procedure-specific sampling technologies restricts broader penetration of semi-automatic instruments. Approximately 42% of high-throughput biopsy environments demonstrate a preference for automated firing where speed and standardized deployment are major priorities. Semi-automatic instruments therefore compete most effectively in procedures where physician-controlled positioning has greater clinical value. Procurement consolidation is another restraint because roughly 33% of larger institutional purchasing programs favor standardized supplier portfolios that bundle needles, guns, localization products, and related procedural accessories. Smaller manufacturers may consequently encounter difficulty securing long-term contracts despite offering technically competitive products.
| Market Restraint | Impact Rank | Negative CAGR Impact | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Competition from fully automatic biopsy guns and alternative tissue-sampling technologies | High | -1.05% | High | High | Medium |
| Cost-sensitive procurement and pricing pressure across hospitals and diagnostic centers | Medium | -0.72% | High | Medium | Medium |
| Limited specialist and image-guided biopsy infrastructure in developing healthcare markets | Low | -0.48% | Medium | Medium | Low |
| Others | Lowest | -0.25% | Low | Low | Low |
| Total Restraint Impact | -2.50% |
Market Challenges
"Balancing specimen quality, needle dimensions, safety and procurement economics"
A central market challenge is achieving consistent tissue yield while minimizing procedural trauma and maintaining competitive procurement economics. Around 56% of clinical product evaluation is influenced by specimen adequacy, deployment precision, penetration characteristics, and needle visibility, whereas approximately 44% is influenced by handling convenience, packaging, supply reliability, and purchasing considerations. Performance requirements also vary substantially by organ, lesion position, imaging modality, and physician technique. Manufacturers must therefore maintain several gauge configurations without creating unnecessary portfolio complexity. Regulatory documentation, sterilization validation, quality consistency, and distribution reliability add further operational demands, particularly for suppliers expanding across multiple healthcare markets with different procurement and compliance expectations.
Segmentation Analysis
The Semi-Automatic Biopsy Instrument Market is segmented by needle diameter and end-user application, with product selection influenced by target anatomy, required specimen volume, imaging method, physician preference, and procedural setting. Diameter 18G products represent approximately 39% of demand and form the largest individual type category, while hospitals account for nearly 58% of application-based utilization. Diagnostic and imaging centers represent another important demand pool as outpatient tissue sampling expands. The segmentation structure demonstrates that no single needle diameter is appropriate for every procedure, sustaining demand for diversified product portfolios and procedure-specific clinical selection.
By Type
Diameter 14G
Diameter 14G semi-automatic biopsy instruments represent approximately 17% of type-based demand. Their larger needle profile supports procedures requiring comparatively substantial tissue cores and can improve specimen volume when clinically appropriate. Utilization is concentrated in selected breast and soft-tissue applications where tissue architecture is particularly important for pathological assessment. Approximately 62% of 14G purchasing considerations relate to specimen adequacy and cutting performance, while the remaining 38% center on handling, penetration characteristics, patient considerations, and procedural compatibility. The segment maintains a specialized but clinically relevant position.
Diameter 16G
Diameter 16G instruments account for approximately 26% of market demand and provide an intermediate option between larger-core and smaller-diameter biopsy approaches. Their use spans liver, kidney, lymph-node, soft-tissue, and selected oncology procedures depending on clinical requirements. Nearly 57% of utilization is associated with procedures where physicians seek a relatively substantial specimen while maintaining manageable needle dimensions. The remaining 43% reflects more procedure-specific selection based on lesion accessibility, tissue characteristics, imaging guidance, and institutional biopsy protocols. This versatility makes 16G products an important component of multi-gauge supplier portfolios.
Diameter 18G
Diameter 18G represents the leading type with approximately 39% of global semi-automatic biopsy instrument demand. The segment benefits from broad applicability across image-guided core biopsy procedures and a practical balance between specimen size and needle dimensions. Around 68% of 18G utilization is associated with hospital and diagnostic-center workflows requiring routine tissue acquisition under imaging guidance. Clinicians value the gauge for procedures where controlled placement and adequate histological material are both important. Its broad procedural suitability also enables distributors and hospitals to maintain standardized inventory without excessive fragmentation across numerous specialized configurations.
Diameter 20G
Diameter 20G instruments account for approximately 18% of type-based demand and are selected where clinicians prioritize a smaller needle profile or where lesion characteristics make a narrower instrument preferable. Approximately 54% of segment demand is associated with targeted procedures in which controlled access and reduced needle dimensions influence selection. The remaining 46% reflects specialized physician preferences and institutional protocols. Although the segment is smaller than 18G, continued improvements in cutting geometry and specimen capture are helping manufacturers address the trade-off between reduced needle diameter and sufficient tissue acquisition for diagnostic assessment.
By Application
Hospitals
Hospitals constitute the largest application segment with approximately 58% of Semi-Automatic Biopsy Instrument Market demand. Their leadership reflects concentrated access to radiology, pathology, oncology, surgery, and multidisciplinary diagnostic services. Around 71% of hospital demand is linked with image-guided or specialist-led biopsy workflows where controlled tissue sampling is required. High procedure volumes also encourage hospitals to evaluate product consistency, sterile packaging, supply continuity, and clinician familiarity alongside acquisition cost. Large institutions frequently maintain several gauge sizes so physicians can select instruments according to target tissue, lesion characteristics, and sampling requirements.
Academic and Research Institutes
Academic and research institutes account for approximately 14% of application demand. These organizations use semi-automatic biopsy instruments in translational research, pathology studies, clinical investigations, and specialized diagnostic programs. Approximately 61% of segment utilization is associated with clinically connected research and teaching environments, while around 39% relates to specialized investigative activities. Although volumes are lower than in hospitals, academic centers can influence product evaluation because specialists assess specimen integrity, procedural technique, needle characteristics, and compatibility with emerging diagnostic approaches. Their involvement also supports clinician training and comparative evaluation of biopsy technologies.
Diagnostic and Imaging Centers
Diagnostic and imaging centers represent approximately 28% of market demand and are becoming increasingly important as healthcare delivery shifts appropriate biopsy procedures into specialized outpatient settings. About 69% of instrument utilization in this segment is associated with ultrasound-guided and other image-assisted tissue sampling. Centers typically prioritize instruments that offer straightforward preparation, reliable deployment, ergonomic handling, and predictable supply. The segment benefits from growing patient preference for focused diagnostic environments and shorter procedural pathways. Suppliers offering consistent disposable systems and multiple needle gauges can effectively address the operational requirements of these centers.
![]()
Semi-Automatic Biopsy Instrument Market Regional Outlook
The Semi-Automatic Biopsy Instrument Market displays distinct regional demand patterns based on diagnostic infrastructure, cancer-screening intensity, imaging availability, healthcare expenditure priorities, and access to trained specialists. North America accounts for approximately 38% of global demand, Europe represents 27%, Asia-Pacific holds 25%, and Middle East & Africa accounts for the remaining 10%, bringing the regional distribution to 100%. Mature markets are characterized by established image-guided biopsy pathways and replacement purchasing, while developing markets provide expansion opportunities through new diagnostic infrastructure and wider access to minimally invasive tissue-sampling procedures.
North America
North America holds approximately 38% of the global Semi-Automatic Biopsy Instrument Market, making it the largest regional segment. The region benefits from mature oncology diagnostics, extensive imaging capacity, strong pathology networks, and widespread availability of minimally invasive procedures. Approximately 73% of regional demand is associated with hospitals and specialized diagnostic facilities conducting image-guided biopsies. Product selection increasingly emphasizes reliable sample acquisition, physician ergonomics, sterile single-use designs, and compatibility with established clinical protocols. Replacement purchasing also supports demand because healthcare institutions regularly evaluate needle performance and standardize biopsy supplies across multiple departments.
Europe
Europe accounts for approximately 27% of global market demand, supported by structured cancer-diagnostic programs, established hospital systems, and extensive radiology services. Approximately 66% of regional semi-automatic biopsy instrument utilization is linked with hospital-based and specialist imaging procedures. Procurement systems place considerable emphasis on clinical performance, quality documentation, sterilization standards, and cost-effective supply arrangements. Western European healthcare systems represent the majority of established consumption, while Central and Eastern European markets provide incremental opportunities as imaging infrastructure improves. Demand remains particularly relevant for multi-gauge portfolios that can support diverse tissue-sampling protocols.
Asia-Pacific
Asia-Pacific represents approximately 25% of global demand and offers substantial expansion potential as diagnostic capacity broadens across major population centers. Around 48% of the region's emerging demand is associated with expansion of hospital imaging, oncology diagnostics, and specialist outpatient services. Large patient populations and improving access to ultrasound-guided procedures support higher instrument utilization, although procurement conditions vary significantly between advanced and developing healthcare systems. Manufacturers that combine dependable clinical performance with efficient distribution and competitive product positioning are well placed to capture demand as minimally invasive biopsy techniques become accessible across a broader range of healthcare facilities.
Middle East & Africa
Middle East & Africa accounts for approximately 10% of the global Semi-Automatic Biopsy Instrument Market. Demand is concentrated in major hospitals, private healthcare networks, oncology centers, and diagnostic facilities in comparatively developed healthcare hubs. Approximately 62% of regional consumption is associated with larger urban medical institutions where specialist radiology and pathology capabilities are available. Expansion of cancer diagnostics and private-sector healthcare investment supports gradual market development, while limited specialist access constrains penetration in less-developed areas. Distributor capability and consistent availability of sterile disposable products remain particularly important competitive factors throughout the region.
List of Key Semi-Automatic Biopsy Instrument Market Companies Profiled
- PAJUNK
- Möller Medical
- Seedos
- MEDITECH DEVICES
- Mdl Srl
- HSI Medical
- Vigeo Srl
- Argon Medical
- STERYLAB
- GEOTEK MEDICAL
Top Companies with Highest Market Share
- Argon Medical: Estimated to represent approximately 16% of the profiled competitive market, supported by broad biopsy-product positioning and established clinical distribution.
- PAJUNK: Estimated to account for approximately 12% of the profiled competitive market, supported by specialization in interventional medical devices and needle-based procedural solutions.
Investment Analysis and Opportunities
Investment opportunities in the Semi-Automatic Biopsy Instrument Market are increasingly connected with product refinement, geographic distribution, outpatient diagnostics, and procedure-specific portfolio expansion. Approximately 34% of emerging commercial opportunity is associated with diagnostic and outpatient environments, where providers require sterile, easy-to-use instruments that integrate efficiently into image-guided workflows. Another 29% is linked with expansion of diagnostic capacity across developing healthcare markets. Investment in echogenic needle visibility, cutting-edge consistency, safety features, and ergonomic firing mechanisms can strengthen product differentiation. Manufacturers can also benefit from broader gauge portfolios because approximately 43% of institutional procurement decisions favor suppliers capable of supporting several biopsy procedures through a consolidated product relationship. Distribution investment is particularly important in Asia-Pacific and Middle East & Africa, where market access depends heavily on local inventory availability, clinician education, regulatory support, and hospital procurement relationships.
New Products Development
New product development is focused on incremental improvements that make semi-automatic biopsy procedures more predictable, convenient, and compatible with modern imaging workflows. Approximately 41% of product-development emphasis is directed toward needle geometry, specimen capture, and penetration performance, while nearly 27% focuses on ergonomic firing systems and physician handling. Another significant development area involves echogenic visibility because image guidance is central to approximately 67% of relevant procedures. Manufacturers are also refining depth-control features, protective mechanisms, packaging configurations, and gauge portfolios. Single-use designs remain important, representing roughly 72% of relevant product preference where infection-control efficiency and simplified preparation influence procurement. Future differentiation is likely to depend on combining dependable tissue acquisition with intuitive handling rather than adding unnecessary mechanical complexity. Companies able to standardize operating characteristics across 14G, 16G, 18G, and 20G variants can also reduce training requirements and support consolidated hospital procurement.
Recent Developments
- November 2025 – Argon Medical biopsy portfolio optimization focus: Product strategy within the semi-automatic biopsy category emphasized procedural consistency, controlled tissue acquisition, and compatibility with image-guided workflows. An estimated 67% of relevant procedures depend on imaging assistance, making needle visibility and predictable deployment increasingly important product-development priorities.
- September 2025 – PAJUNK needle-design and procedural usability focus: Competitive development activity centered on ergonomic handling, controlled needle placement, and specialist procedural requirements. Approximately 59% of product-selection criteria across the category are associated with sample reliability, deployment characteristics, imaging visibility, and clinician handling, encouraging continued refinement of needle-based systems.
- June 2025 – Möller Medical diagnostic workflow development focus: Market-facing product development increasingly emphasized efficient integration of biopsy instruments into minimally invasive diagnostic workflows. Approximately 31% of emerging procedural opportunities are associated with outpatient or specialist diagnostic environments, strengthening the commercial importance of compact, sterile, straightforward biopsy configurations.
- October 2024 – STERYLAB disposable biopsy solution development focus: Product positioning across biopsy procedures increasingly reflected healthcare demand for sterile single-use instruments and simplified preparation. Disposable configurations account for an estimated 72% of relevant procedural preference, supporting development priorities around packaging efficiency, infection-control management, reliable activation, and consistent specimen acquisition.
- May 2024 – GEOTEK MEDICAL multi-gauge biopsy portfolio focus: Competitive product activity emphasized broader gauge availability for different tissue-sampling requirements. Diameter 18G instruments represent approximately 39% of demand, while 14G, 16G, and 20G configurations collectively represent approximately 61%, demonstrating the commercial importance of maintaining diversified needle-size portfolios.
Report Coverage
The Semi-Automatic Biopsy Instrument Market report evaluates market structure, product demand, competitive positioning, clinical utilization, segmentation, regional patterns, investment priorities, and product-development opportunities. Type coverage includes Diameter 14G, Diameter 16G, Diameter 18G, and Diameter 20G instruments, with estimated shares of approximately 17%, 26%, 39%, and 18%, respectively. Application analysis covers hospitals, academic and research institutes, and diagnostic and imaging centers, representing approximately 58%, 14%, and 28% of demand. Regional analysis evaluates North America at approximately 38%, Europe at 27%, Asia-Pacific at 25%, and Middle East & Africa at 10%, providing a complete 100% global distribution framework. Competitive coverage includes PAJUNK, Möller Medical, Seedos, MEDITECH DEVICES, Mdl Srl, HSI Medical, Vigeo Srl, Argon Medical, STERYLAB, and GEOTEK MEDICAL. The analysis also assesses image-guided biopsy adoption, disposable instrument preference, outpatient procedure expansion, procurement behavior, needle-gauge selection, specimen-quality requirements, physician ergonomics, safety considerations, distribution capabilities, and diagnostic infrastructure. Approximately 67% of relevant procedural activity is associated with image-guided workflows, while disposable configurations represent about 72% of applicable instrument preference, highlighting the two operational themes most influential to product positioning and future competitive development.
Semi-Automatic Biopsy Instrument Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 121.63 Million in 2026 |
|
|
Market Size Value By |
USD 165.77 Million by 2035 |
|
|
Growth Rate |
CAGR of 3.5% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Download FREE Sample
Frequently Asked Questions
-
What value is the Semi-Automatic Biopsy Instrument Market expected to touch by 2035?
The global Semi-Automatic Biopsy Instrument Market is expected to reach USD 165.77 Million by 2035.
-
What CAGR is the Semi-Automatic Biopsy Instrument Market expected to exhibit by 2035?
The Semi-Automatic Biopsy Instrument Market is expected to exhibit a CAGR of 3.5% by 2035.
-
Who are the top players in the Semi-Automatic Biopsy Instrument Market?
PAJUNK, Möller Medical, Seedos, MEDITECH DEVICES, Mdl Srl, HSI Medical, Vigeo Srl, Argon Medical, STERYLAB, GEOTEK MEDICAL
-
What was the value of the Semi-Automatic Biopsy Instrument Market in 2025?
In 2025, the Semi-Automatic Biopsy Instrument Market value stood at USD 117.52 Million.
About the Author(s):
This report was authored by the Healthcare Research Team at Global Growth Insights. The team specializes in pharmaceuticals, biotechnology, medical devices, diagnostics, digital health, healthcare services, and life sciences. Their expertise includes market sizing, regulatory analysis, competitive benchmarking, and healthcare trend forecasting to support strategic investment and business growth.
Our Clients
Download FREE Sample